Argenx Se ARGX
NASDAQ ARGX
$1,033.15 -20.31 (-1.93%)
At close: Sep 4, 2026 · 4:00 PM EDT

Argenx Se (ARGX) Receivables (2015 - 2026)

Argenx Se's (ARGX) quarterly Receivables came in at $1.9 billion in Q2 2026, down 99.84% on a YoY basis from $1197.1 billion in Q2 2025, and up 17.24% quarter-over-quarter from $1.6 billion in Q4 2025.

Analysis

Argenx Se (ARGX) Receivables (2015 - 2026) Analysis & Trends

Argenx Se (ARGX) has reported Receivables for 12 consecutive years, with $1.9 billion the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Receivables fell 99.84% year-over-year to $1.9 billion; the trailing twelve-month figure through Jun 2026 stood at $1.9 billion (down 99.84% YoY), and the FY2025 full-year result was $1.6 billion, down 99.82% from the prior year.
  • Receivables improved to $1.9 billion in Q2 2026 per ARGX's latest filing, from $1.6 billion in the prior quarter.
  • Across five years, Receivables topped out at $1197.1 billion in Q2 2025 and bottomed at $112.4 million in Q2 2022.
  • Historically, Receivables has averaged $133.7 billion across 5 years, with a median of $652.9 million in 2024.
  • The sharpest annual moves came in 2025 and 2026: Receivables jumped 183253.63% in 2025, then tumbled 99.84% in 2026.
  • Over 5 years, Receivables stood at $275.7 million in 2022, then surged by 80.16% to $496.7 million in 2023, then surged by 82.1% to $904.5 million in 2024, then jumped by 82.1% to $1.6 billion in 2025, then grew by 17.24% to $1.9 billion in 2026.
  • According to Business Quant data, Receivables over the past three periods registered $1.9 billion, $1.6 billion, and $1197.1 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn 10.23 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn 5.90 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn 2.13 Bn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn 6.57 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn 1.93 Bn
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn 160.00 Mn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn 912.74 Mn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn 1.89 Bn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn 215.33 Mn
10 BioNTech SE 26.24 Bn 12.58 Bn 10.00 Mn 190.51 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.93 Bn
Dec 31, 2025 1.65 Bn
Jun 30, 2025 1,197.07 Bn
Dec 31, 2024 904.47 Mn
Jun 30, 2024 652.88 Mn
Dec 31, 2023 496.69 Mn
Jun 30, 2023 353.23 Mn
Dec 31, 2022 275.70 Mn
Jun 30, 2022 112.39 Mn
Dec 31, 2021 38.22 Mn
Jun 30, 2021 12.05 Mn
Dec 31, 2020 6.78 Mn
Jun 30, 2020 9.43 Mn
Dec 31, 2019 34.04 Mn
Jun 30, 2019 5.93 Mn
Dec 31, 2018 6.30 Mn
Jun 30, 2018 15.19 Mn
Dec 31, 2017 6.52 Mn
Jun 30, 2017 4.69 Mn
Dec 31, 2016 2.13 Mn